This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's What Could Help Merck KGaA (MKGAF) Maintain Its Recent Price Strength
by Zacks Equity Research
Merck KGaA (MKGAF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Merck KGaA (MKGAF) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Merck KGaA (MKGAF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Merck KGaA (MKGAF) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Merck KGaA (MKGAF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
HEXO (HEXO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of -900% and 15.51%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of 30.77% and 11.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -29.55% and 23.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -36% and 1.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -11.43% and 42.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Moves 9.4% Higher: Will This Strength Last?
by Zacks Equity Research
Profound Medical (PROF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bears are Losing Control Over Merck KGaA (MKGAF), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Merck KGaA (MKGAF) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Consumer Price Inflation Really Matters
by John Blank
What CPI index groups should you consult?
The Zacks Analyst Blog Highlights Banco Do Brasil, Merck KGaA and Ecopetrol
by Zacks Equity Research
Banco Do Brasil, Merck KGaA and Ecopetrol are included in this Analyst Blog.
Big Banks Show Q3 Earnings: Global Week Ahead
by John Blank
U.S. inflation numbers, retail sales data, consumer sentiment gauges and minutes from the Federal Reserve's latest meeting will give market watchers plenty to chew on.
Big Banks Show Q3 Earnings: Global Week Ahead
by John Blank
U.S. inflation numbers, retail sales data, consumer sentiment gauges and minutes from the Federal Reserve's latest meeting will give market watchers plenty to chew on.
Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval
by Zacks Equity Research
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval
by Zacks Equity Research
Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.
Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study
by Zacks Equity Research
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.
Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review
by Zacks Equity Research
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets priority review in the United States. The decision is expected in June.
Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate
by Zacks Equity Research
Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.
Pfizer's (PFE) New Lung Cancer Drug Vizimpro Gets CHMP Nod
by Zacks Equity Research
Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets recommendation from CHMP of the EMA.
Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds
by Zacks Equity Research
Merck KGaA (MKGAF) inks an exclusive licensing agreement with Vertex for two DNA-dependent protein kinase inhibitors in the field of gene editing for six specific genetic disease indications.
5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock
by Zacks Equity Research
Here are five aspects that investors may consider while investing in Pfizer's (PFE) stock.
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
by Zacks Equity Research
In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.
Pfizer's Drug Combo Betters Survival in Kidney Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.